Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07075445 · ClinicalTrials.gov registry record

Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3

A clinical trial of Long QT Syndrome Type 3 and Long QT Syndrome 2, sponsored by Thryv Therapeutics.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT07075445 is a study of Long QT Syndrome Type 3 and Long QT Syndrome 2 that is actively recruiting participants, run by Thryv Therapeutics. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07075445, a study of Long QT Syndrome Type 3 and Long QT Syndrome 2, is actively recruiting participants, sponsored by Thryv Therapeutics.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3. Each participant will answer each patient-reported outcome questionnaire only once over a 6-month period. The study will enroll up to 200 participants.

Study Locations (1)

North Carolina

  • East Carolina University - Greenville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-10-27
Est. Completion 2026-12-01

Sponsor

Thryv Therapeutics

5 total trials

What the Registry Record Tells You About NCT07075445

The ClinicalTrials.gov registry entry for NCT07075445 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thryv Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Long QT Syndrome Type 3 appearing as the primary indexed condition, and to 0 interventions.

NCT07075445 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT07075445 about?

NCT07075445 is a clinical study titled "Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3". This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3. Each participant will answer each patient-reported outcome questionnaire only once over a 6-month period. The study will enroll up to 200 participants.

What is the current status of trial NCT07075445?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-10-27. Estimated completion is 2026-12-01.

What conditions does trial NCT07075445 study?

This clinical trial studies the following conditions: Long QT Syndrome Type 3, Long QT Syndrome 2.

Who is sponsoring clinical trial NCT07075445?

This trial is sponsored by Thryv Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07075445 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.